Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.
García-Corbacho J, Indacochea A, González Navarro AE, Victoria I, Moreno D, Pesántez D, Angelats L, Modrego-Sanchez A, Sanfeliu E, Castillo O, Blasco P, Mezquita L, Viñolas N, Nogué M, Galván P, Adamo B, Basté N, Sauri T, Juan M, Prat A, Schettini F.
García-Corbacho J, et al. Among authors: vinolas n.
Cancer Immunol Immunother. 2023 Jun;72(6):1725-1726. doi: 10.1007/s00262-023-03396-5.
Cancer Immunol Immunother. 2023.
PMID: 36809405
Free PMC article.
No abstract available.